MLL is fused to ENL or ELL in acute leukemias that contain t(l1; 191(q23;p131. Although ENL and ELL localize to chromosome 19, bands p13.3 and p13.1, respectively, these breakpoints are not always readily distinguished by standard cytogenetics. We therefore used reversa transcriptasepolymerase chain reaction (RT-PCR) assays to analyze 26 cases of childhood acute leukemia containing t(l1; 19) to determine the frequencies of ENL and ELL involvement. All 17 cases of acute lymphoblastic leukemia (ALL) had MLLIENL RANSLOCATIONS involving chromosome 11, band T q23, are seen in the majority of cases of infant acute lymphoblastic leukemia (ALL) and topoisomerase-induced secondary acute myelogenous leukemia (AML).'-6 1 lq23 translocations also occur, albeit less frequently, in de novo AML and in ALL in older patients. In both ALL and AML, the majority of 1 lq23 translocations disrupt the MLL gene (also referred to as ALL-I, HRX, and HTRXI), which encodes a 43 1-kD protein with significant homology to Drosophila t r i t h~r a x .~ Structural motifs within MLL suggest that its normal functions are mediated through a direct interaction with DNA. These motifs include three AT hooks near the N-terminus that may mediate binding to AT-rich DNA sequences, a central zinc-finger domain, and a region of 47 amino acids between the AT hook and zinc-finger motifs that has homology to the noncatalytic domain of human DNA-methyltransfera~e.~~~." In addition, functional studies have localized a repression domain between the AT hooks and the zinc fingers, as well as a strong activation domain C-terminal to the zinc-finger motifs.12
T q23, are seen in the majority of cases of infant acute lymphoblastic leukemia (ALL) and topoisomerase-induced secondary acute myelogenous leukemia (AML).'-6 1 lq23 translocations also occur, albeit less frequently, in de novo AML and in ALL in older patients. In both ALL and AML, the majority of 1 lq23 translocations disrupt the MLL gene (also referred to as ALL-I, HRX, and HTRXI), which encodes a 43 1-kD protein with significant homology to Drosophila t r i t h~r a x .~ Structural motifs within MLL suggest that its normal functions are mediated through a direct interaction with DNA. These motifs include three AT hooks near the N-terminus that may mediate binding to AT-rich DNA sequences, a central zinc-finger domain, and a region of 47 amino acids between the AT hook and zinc-finger motifs that has homology to the noncatalytic domain of human DNA-methyltransfera~e.~~~." In addition, functional studies have localized a repression domain between the AT hooks and the zinc fingers, as well as a strong activation domain C-terminal to the zinc-finger motifs. 12 Although the normal physiologic role of MLL is currently unknown, 1 lq23 translocations fuse similar portions of MLL, encoding the AT hooks and methyltransferase domains to a variety of partner gene^.^,^ The most common 1 lq23 translocations include the t(4; 1 l), t(9; 1 l), and t(l1; 19). In the t(4; 1 l), MLL is fused to a portion of the AF-4 gene (also called FEL), which encodes a 140-kD protein that lacks homology to known proteins, but is rich in serinelproline and has two consensus nuclear localization signal^.'^'^ The partner genes involved in the t(9;ll) and the t(11;19) (q23; p 13.3), AF-9 and ENUMLLTIILTGI 9, respectively, also encode serinelproline-rich proteins that contain nuclear localization signals.'4," In addition, ENL and AF-9 share 56% identity in their 140 N-terminal amino acids and 82% identity in their 67 C-terminal amino acids, further suggesting that these proteins have similar biologic functions. Moreover, ENL contains a transactivation domain that is localized to the C-terminal region of homology with AF-9 and is retained in both the MLLIENL and MLLIAF-9 fusion products." Although these data suggest that fusion partners contribute a transcriptional regulatory motif to the chimeric products, analysis of other fusion products encoded by rarer 1 lq23 translocations suggest no unifying function for them.' Careful cytogenetic analyses suggest that 11; 19 translocations can involve chromosome 19 band p13.3 in both AML and ALL, or band 19p 13. I in AML; however, this distinction may be difficult to assess cytogenetically.I6 The t(1 I ; 19) (q23;p13.1) has recently been cloned and shown to result in a chimeric gene involving MLL and ELL, a novel gene that encodes an arginine-rich, basic protein that has homology within its C-terminal portion to the DNA-binding domain of poly(ADP-ribose) polymerase, suggesting that it may also function through direct interactions with ELL also shares homology with arginine-rich nuclear protein, which is thought to be involved in RNA processing. Thus, the t(l1; 19)(q23;p13.1) may create a novel chimeric transcription factor that leads to AML.
To date, MLLIELL chimeric transcripts have only been identified in four adult AML patients, one of whom may have had therapy-induced AML following treatment with etoposide. 17 Similarly, cytogenetic analysis of 42 cases of leukemia with 1 1 ; 19 translocations showed the 19~13.1 breakpoint in 13 patients, all of whom had AML." Moreover, 9 of these 13 patients were older than 16 years, suggesting that MLLIELL fusions occur primarily in adults with AML. However, no molecular studies were performed on these cases.
To directly determine the relative frequency of ENL and ELL involvement in 1 I; 19 ENL mRNA was expressed in leukemic blasts from 17 ALLs and 6 AMLs, whereas MLUELL mRNA was detected in only 2 cases of AML. Furthermore, among eight infants analyzed, all had MLUENL fusion transcripts.
MATERIALS AND METHODS
P d e n t specimens. Cryopreserved diagnostic bone marrow specimens from 26 patients with ALL. de novo AML, or secondary AML treated on St Jude Children's Research Hospital (SJCRH) or Pediatric Oncology Group (POG) protocols were analyzed. Case selection was based on sample availability and cytogenetically detected t( l l: 19). Nine cases were available from the SJCRH cell bank and 17 from the POG.
Bone marrow samples were analyzed directly or after a 24-hour culture as previously described." Analyses were performed either at SJCRH or at the POG reference cytogenetics laboratory in Birmingham, AL.
Genomic DNA was analyzed for MLL rearrangements by Southern blot analysis as previously described." Briefly, high-molecular-weight DNA was digested with BamHI, electrophoretically separated in agarose gels, transferred to nylon membranes, and hybrized with a 0.74-kb BamHI MLL cDNA probe that spans exons 5 through 1 1
Total RNA was extracted, cDNA synthesized, and RT-PCR performed as previously described." Individual PCR reactions to detect MLUENL or MLUELL cDNA products all used MLLa as the 5' primer ( Table I , Fig 1) . ENLal and ENLa2 (Table  I , Fig I ) were used as 3' primers to detect the two types of MLU ENL fusions. Primer pair MLLa:ENLaI amplifies products that fuse MLL to the 5' region of ENL (at nucleotide 13),' whereas primer pair MLLa:ENLa2 detects the more distal breakpoint in ENL (fused at nt 1 I 1 I)." Primers ELLa and ELLb (Table I , Fig I ) were designed to amplify MLUELL fusions" in standard (ELLa) or semi-nested (ELLa followed by ELLb) RT-PCR. In a separate reaction, the cABL mRNA was amplified as a control for the presence of amplifiable RNA.
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RESULTS
Material from 26 pediatric patients whose leukemic blasts contained the t( 11; 19) were obtained from the cell banks of St Jude Children's Research Hospital or the Pediatric Oncology Group. None of these cases were included in the report of Huret et al." Seventeen cases of ALL and nine cases of AML were analyzed, with an age range of less than 1 month to 18 years ( Table 2 ). This analysis included seven infants less than a year old, all of whom had ALL.
Southern blot analysis of BamHI-digested genomic DNA hybridized with a 0.74-kb MLL cDNA probe revealed evidence of MLL gene rearrangements in each case (data not shown). To define the type of fusion transcript encoded by the 1 1 ; 19 translocation, we performed RT-PCR analysis on total RNA extracted from these cases using pairs of oligonucleotides for either the MLUENL or the MLUELL mRNA ( Table 1) . Two ENL breakpoints have been described and shown to encode different MLUENL mRNAs (Fig  We  therefore (Fig 1) . In addition, cases that were negative with the previously described reactions were subjected to a semi-nested PCR reaction using an internal 3' ELL primer, ELLb, and the 5' MLLa primer to increase the sensitivity of amplification of the MLUELL message (Fig 1) .
A representative Southern blot of RT-PCR products is shown in Fig 2. Lanes I to 5 show a 570-bp product amplified by primer pair MLLa:ENLal. Although PCR products were not sequenced, this product is the predicted size of an MLUENL transcript that fuses MLL exon 8 to ENL nucleo- 
DISCUSSION
MLL gene rearrangements are among the most common genetic lesions in acute leukemia, with chimeric genes formed with over 20 different chromosomal loci! One of the more common reciprocal translocations involving 1 lq23 is the t ( 1 I ; 19) . Recent cytogenetic and molecular data has revealed that this translocation can involve two different genes, ENL and ELL, on chromosome 19.".'* Using RT-PCR assays for the t( I 1 ; 19)-encoded MLUENL and MLU ELL mRNAs, we now show that in pediatric acute leukemia patients, MLUENL fusion transcripts predominate, being detected in each of the 17 ALL cases analyzed, and in 6 of 9
Abbreviations: AML, acute myeloid leukemia; ALL, B-lineage acute lymphoblastic leukemia; T-ALL, T-cell ALL: t-AML, therapy-related AML.
Age at diagnosis, in years unless specified as months (mo). Overall. 23 of 26 cases had RT-PCR-detectable MLU ENL fusion transcripts, whereas only two cases had MLU ELL fusions, one of which required nested PCR for detection ( Table 2 ). All of the 17 ALL cases, which included 7 infants, 4 cases of T-cell ALL, and 6 cases of B-lineage ALL, expressed MLUENL fusions. Overall, 23 cases expressed MLU ENL fusions, of which 19 had proximal breakpoints in ENL that were detected with the MLLa:ENLal primer pair. The Molecular analysis of the structure of the predominant MLLJENL mRNAs revealed that most cases expressed mRNAs that were likely fused to ENL at nucleotide 13, and thus were amplifiable by the 3' ENLa primer. By contrast, four cases were identified that contained fusion transcripts amplifiable only with the 3' ENLb primer, and thus may represent fusion of MLL sequences to ENL nucleotide 1 1 1 1. However, because sequencing of the PCR products was not performed, the fusion points may differ slightly from those previously reported for MLUENL fusions. The structure of this latter chimeric product suggests that the critical features of ENL that contribute to MLLJENL reside in the C-terminal 189 amino acids. Functional studies have localized a transactivation domain to the C-terminal 90 amino acids of ENL, a region that is nearly identical to the C-terminal portion of AF-9.I4.I5 However, since no transforming assays have been developed for the MLL fusion proteins, the contribution of the ENL transactivation domain to the transforming activity of MLLJENL remains unknown.
The newly described fusion partner, ELL, shares no homology with any of the previously cloned MLL partner genes.'73'' Although functional studies have not been performed, sequence analysis suggests that ELL contributes a basic lysine-rich DNA-binding domain to the fusion proteir~.'~.'' As is the case for ENL, the role of this domain in transformation awaits the development of appropriate assays.
One case was identified that contained cytogenetic evidence oft( l l ; 19) and had an MLL rearrangement, but lacked both the MLUENL and MLUELL fusion transcripts. On review, this case had a 19~13.1 breakpoint and likely has an altemative breakpoint in ELL that is unable to be amplified by the oligonucleotide primers used in our analysis. Insufficient material was available on this case to further investigate this possibility.
The presence of 1 lq23 rearrangements within leukemic blasts of pediatric ALL patients identifies a distinct group with a poor response to conventional therapy? Recent data suggests that the critical lesion is a rearrangement of the MLL gene and not simply cytogenetic evidence of a structural abnormality of 1 1q23.24 For example, patients with deletions and inversions of chromosome llq23 lack MLL gene rearrangements and have a favorable 0utcome.2~ Thus, appropriate treatment of pediatric ALL patients using risk-stratified treatment approaches requires characterization of the status of the MLL gene within the leukemic blasts. The development here of RT-PCR-based assays to detect both MLU ENL and MLUELL fusion transcripts should therefore be valuable in the characterization of newly diagnosed patients with leukemia.
